HeartWay Medical-B (06609) Issues Profit Warning: Expected 2025 Revenue of RMB 400–410 Million, Up at Least 43.9% Year-over-Year

HeartCare-B (06609) announced that the group expects to achieve revenue between approximately RMB 400 million and RMB 410 million for the year ended December 31, 2025 (the reporting period), representing an increase of at least 43.9% compared to the revenue of RMB 278 million for the year ended December 31, 2024. The group also anticipates achieving a pre-tax profit of approximately RMB 80 million during the reporting period, which marks a significant increase compared to the pre-tax net loss of RMB 12 million for the year ended December 31, 2024.

The revenue growth was driven by the following factors: the launch of new products and technologies for ischemic stroke and the increased market share of ischemic stroke products; the scaled commercialization of intracranial stents and the increase in sales of other hemorrhagic stroke products; the continued growth in sales of interventional access products; and the Group's effective cost control measures in sales, cost, and administrative expenses, which reduced the Group's expense ratio.